HDAC3 and primary cutaneous T-cell non-Hodgkin lymphoma: Ultimately, having HDAC1/2 versus HDAC3 selective inhibitors will provide flexibility in defining the best schedules and combinations of these compounds to maximize the therapeutic benefit in the treatment of CTCL.